Centrally-Authorised Procedure (CAP)
Centrally-Authorised Procedure (CAP)
A centralised procedure is an EU procedure type where the EMA (European Medicine Agency) reviews and approves applications on behalf of all EU member states.
“Certain drugs, such as biotechnology, HIV/AIDS, cancer and diabetes, require submission as a centralised procedure.”
More information about Centrally-Authorised Procedure (CAP)
Products,procedures,application,market,medicine,period,actions,Medicinal product,centralised procedure,assessment report,submission.
Approach,assessment,opinion,authority,approval,Northern Ireland,list of products,renewal applications,assessment process,class of medicines,activity,Centrally Authorised Products,products subject,Community Marketing Authorisations.
Study,positive opinion,competent authorities,European Commission,reliance route,clinical trials,single marketing authorisation,centralised route,regulatory route,generic products,individual products,marketing products,pharmaceutical product,decentralised procedure,national authorisation procedure,national procedure,referral procedures,Centralized procedure,mutual recognition procedures,relevant procedures,variation applications,centralised applications,ownership application,application forms,application routes,future applications,assessment routes,flight assessment.
Scientific assessment,innovative medicines,access to medicines,generic medicines,orphan medicines,regulatory activities,sequence submission,baseline submission,Health Food Manufacturers’ Association,public health,European markets,routes to market,format,Medicinal Products,Reference Medicinal Products,community,packaging,compliant packaging,surveillance programme,grandfathering process,grandfathering of CAPs,guidance on grandfathering,clinical studies,post-authorisation safety study,minimal initiating sequence,transition period,90-day period,monitoring,risk-based approach,Commission,benefit-risk balance,healthcare professionals,regulators,medical devices regulator,schedule,urgent safety grounds,effectiveness of risk minimisation,British Generic Manufacturers Association,Customer Services Centre at RIS.NA@mhra.gov.uk,exit day,marketing status,”NPA):email@example.com,Proprietary Association of Great Britain”,pharmaceutical ingredient,European authorisation routes,centralised marketing authorisations,national route,periodic safety update report,60-day process,renewal process,Committee for Medicinal,committee responsible,active products,Reference product,product information update,product to patients,bulk product,chemical products,drug product,product trade,Centralised authorisation procedure,authorisation procedure,European procedures,electronic application form,application for renewal,initial application,independent assessment,In-Flight Assessment,provisional assessment decision,PRAC Pharmacovigilance Risk Assessment Committee,safety of medicines,list of medicines,medicine development,impact of pharmacovigilance activities,additional risk minimisation activities,planning of pharmacovigilance activities,risk management activities,submission package,frequency of submission,electronic health records,public health impact,public health protection,Croatian market,electronic format,file format,pdf format,Community Authorisation,community code,outer packaging,packaging labels,annual programme,programmes,Regular programme,grandfathering,pharmacoepidemiological studies,initiating,complete initiating sequence,divergent opinion,regulatory authority,additional monitoring,literature monitoring service,regulatory actions,Applicant action,approach to variations,Commission Decision,marketing authorisation approval decision,initial approval,benefit-risk,benefit-risk profile,direct healthcare,healthcare payers,international regulators,CHM schedule,fee schedule.